Joana Valente

Dr. Joana Valente

Centre for Rapid and Sustainable Product Development, Polytechnic Institute of Leiria, Leiria, Portugal
orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2012 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
Joana ValenteJoana Valente
Joana Valente
TVT.A.M. Valente
T.A.M. Valente
Patrícia AlvesPatrícia Alves
Patrícia Alves
Paula FerreiraPaula Ferreira
Paula Ferreira
Abilio P. SilvaAbilio P. Silva
Abilio P. Silva
ICIlídio Correia
Ilídio Correia

1 January 2013 in Polymer
Verified
Journal Article
Closed access
Joana ValenteJoana Valente
Joana Valente
Vítor GasparVítor Gaspar
Vítor Gaspar
BAB.P. Antunes
B.P. Antunes
PCP. Countinho
P. Countinho
ICIlídio Correia
Ilídio Correia

26 October 2018 in Current Drug Targets
Verified
Journal Article
Closed access
PDF file
Joana ValenteJoana Valente
Joana Valente
JQJoão A. Queiroz
João A. Queiroz
Fani SousaFani Sousa
Fani Sousa
Background: Several gene deviations can be responsible for triggering oncogenic processes. However, mutations in tumour suppressor genes are usually more associated to malignant diseases, being p53 one of the most affected and studied element. p53 is implicated in a number of known cellular functions, including DNA damage repair, cell cycle arrest in G1/S and G2/M and apoptosis, being an interesting target for cancer treatment. Objective: Considering these facts, the development of gene therapy approaches focused on p53 expression and regulation seems to be a promising strategy for cancer therapy. Results: Several studies have shown that transfection of cancer cells with wild-type p53 expressing plasmids could directly drive cells into apoptosis and/or growth arrest, suggesting that a gene therapy approach for cancer treatment can be based on the re-establishment of the normal p53 expression levels and function. Up until now, several clinical research studies using viral and non-viral vectors delivering p53 genes, isolated or combined with other therapeutic agents, have been accomplished and there are already in the market therapies based on the use of this gene. Conclusion: This review summarizes the different methods used to deliver and/or target the p53 as well as the main results of therapeutic effect obtained with the different strategies applied. Finally, the ongoing approaches are described, also focusing the combinatorial therapeutics to show the increased therapeutic potential of combining gene therapy vectors with chemo or radiotherapy.

29 November 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Ana Catarina SousaAna Catarina Sousa
Ana Catarina Sousa
SBSara Isabel da Silva Biscaia
Sara Isabel da Silva Biscaia
Rui AlvitesRui Alvites
Rui Alvites
MBMariana Esteves Vieira Branquinho
Mariana Esteves Vieira Branquinho
Bruna LopesBruna Lopes
Bruna Lopes
Ana Colette MaurícioAna Colette Maurício
Ana Colette Maurício
Notwithstanding the advances achieved in the last decades in the field of synthetic bone substitutes, the development of biodegradable 3D-printed scaffolds with ideal mechanical and biological properties remains an unattained challenge. In the present work, a new approach to produce synthetic bone grafts that mimic complex bone structure is explored. For the first time, three scaffolds of various composition, namely polycaprolactone (PCL), PCL/hydroxyapatite nanoparticles (HANp) and PCL/HANp/diacrylate poly(ethylene glycol) (PEGDA), were manufactured by extrusion. Following the production and characterisation of the scaffolds, an in vitro evaluation was carried out using human dental pulp stem/stromal cells (hDPSCs). Through the findings, it was possible to conclude that, in all groups, the scaffolds were successfully produced presenting networks of interconnected channels, adequate porosity for migration and proliferation of osteoblasts (approximately 50%). Furthermore, according to the in vitro analysis, all groups were considered non-cytotoxic in contact with the cells. Nevertheless, the group with PEGDA revealed hydrophilic properties (15.15° ± 4.06) and adequate mechanical performance (10.41 MPa ± 0.934) and demonstrated significantly higher cell viability than the other groups analysed. The scaffolds with PEGDA suggested an increase in cell adhesion and proliferation, thus are more appropriate for bone regeneration. To conclude, findings in this study demonstrated that PCL, HANp and PEGDA scaffolds may have promising effects on bone regeneration and might open new insights for 3D tissue substitutes.

5 March 2021 in Polymers
Verified
Journal Article
Open access
PDF file
Joana ValenteJoana Valente
Joana Valente
Patrícia Alexandra Nunes PereiraPatrícia Alexandra Nunes Pereira
Patrícia Alexandra Nunes Pereira
Ângela SousaÂngela Sousa
Ângela Sousa
JQJ.A. Queiroz
J.A. Queiroz
Fani SousaFani Sousa
Fani Sousa
Gene therapy could be simply defined as a strategy for the introduction of a functional copy of desired genes in patients, to correct some specific mutation and potentially treat the respective disorder. However, this straightforward definition hides very complex processes related to the design and preparation of the therapeutic genes, as well as the development of suitable gene delivery systems. Within non-viral vectors, polymeric nanocarriers have offered an ideal platform to be applied as gene delivery systems. Concerning this, the main goal of the study was to do a systematic evaluation on the formulation of pDNA delivery systems based on the complexation of different sized plasmids with chitosan (CH) or polyethyleneimine (PEI) polymers to search for the best option regarding encapsulation efficiency, surface charge, size, and delivery ability. The cytotoxicity and the transfection efficiency of these systems were accessed and, for the best p53 encoding pDNA nanosystems, the ability to promote protein expression was also evaluated. Overall, it was showed that CH polyplexes are more efficient on transfection when compared with the PEI polyplexes, resulting in higher P53 protein expression. Cells transfected with CH/p53-pDNA polyplexes presented an increase of around 54.2% on P53 expression, while the transfection with the PEI/p53-pDNA polyplexes resulted in a 32% increase.

16 August 2022 in Polymers
Verified
Journal Article
Open access
PDF file
Carolina FerreiraCarolina Ferreira
Carolina Ferreira
SGSara Guerreiro
Sara Guerreiro
Joana ValenteJoana Valente
Joana Valente
Tatiana Marisa Fernandes PatrícioTatiana Marisa Fernandes Patrício
Tatiana Marisa Fernandes Patrício
Nuno AlvesNuno Alves
Nuno Alves
Juliana  DiasJuliana Dias
Juliana Dias
The pandemic situation caused by coronavirus clearly demonstrated the need for alternatives able to protect the respiratory tract and inactivate the infectious agents. Based on this, antibacterial face-mask filters of polycaprolactone (PCL) dopped with magnesium oxide (MgO) and copper oxide (CuO) nanoparticles (NPs) were produced using an electrospinning technique. A morphological analysis of electrospun meshes evaluated the success of nanoparticles’ incorporation as well as the average fibers’ diameters (481 ± 272 nm). The performance of electrospun nanofibers was also assessed in terms of tensile strength (0.88 ± 0.25 MPa), water vapor permeability (11,178.66 ± 35.78 g·m−2·day−1), stability under wet conditions and antibacterial activity according to the standard guidelines. The filters showed structural stability up to 2 h of washing and improved antibacterial activity against Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) for optimized concentrations of MgO and CuO NPs. Overall, electrospun meshes with antibacterial activity were successfully developed for advanced filtering applications.